Our advice for clinicians on the coronavirus is here.
If you are a member of the public looking for information and advice about coronavirus (COVID-19), including information about the COVID-19 vaccine, go to the NHS website. You can also find guidance and support on the GOV.UK website.
NHS England has today agreed plans to save hundreds of millions of pounds each year by recommending low value treatments, including fish oil, herbal remedies and homeopathy no longer be provided on the NHS, and launching a consultation on curbs to prescriptions for some ‘over the counter’ products such as paracetamol.
GPs issued 1.1 billion prescription items at a cost of £9.2 billion in 2015/16. The vast majority were appropriate but many were for medicines, products or treatments that do not require a prescription and can be purchased over the counter from pharmacies, supermarkets, petrol stations, corner shops or other retailers in some cases at a much lower cost than the price paid by the NHS.
The NHS could save around £190 million a year by cutting such prescriptions for minor, short-term conditions, many of which will cure themselves or cause no long term effect on health.
Over the counter products currently prescribed include cough mixture and cold treatments, eye drops, laxatives and sun cream lotions. A detailed follow-up consultation on an initial list of conditions will be launched in the New Year.
This will also free up millions of GP appointments that are currently taken up with prescribing these medicines.
NHS England will now press ahead with guidance to GPs and CCGs to remove 18 ineffective, unsafe and low clinical value treatments, such as some dietary supplements herbal treatments and homeopathy, saving up to £141 million a year.
These savings form a key building block of the NHS’s 10 point efficiency plan contained in the Next Steps on the NHS Five Year Forward View, published in March 2017. They will be redeployed into frontline patient care.
NHS England chief executive Simon Stevens, said: “The NHS is one of the most efficient health services in the world but we’re determined to make taxpayers’ money go further. The NHS should not be paying for low value treatments and it’s right that we look at reducing prescriptions for medicines that patients can buy for a fraction of the price the NHS pays.”
Dr Graham Jackson, NHSCC co-chair and clinical chair of NHS Aylesbury Vale CCG, said: “The guidance launched today, which resulted from work we initiated on behalf of our members, will support clinical commissioners in their work to prioritise effectively and make sure they are getting the best value for their medicines spend.
“We were pleased by the volume of responses to the consultation, which gave an opportunity to take into account and reflect the views of public, patients and clinicians and key stakeholders in the final guidance. We need to carry on having these honest open conversations on what the NHS can and should provide with the funding it has, so that we can continue to deliver high quality care.”
The over the counter medicines proposals for consultation include stopping the routine prescribing of products that
- Can be purchased over the counter, and sometimes at a lower cost than that which would be incurred by the NHS – paracetamol is an average of four times as expensive when provided on prescription by the NHS, compared to when it is purchased in pharmacies or supermarkets. It can costs around £34 for 32 on prescription including dispensing and GP consultation fees.
- Treat a condition that is considered to be self-limiting, so does not need treatment as it will heal/be cured of its own accord, such as a common cold.
- Treat a condition which could be managed by self-care, i.e. that the person does not need to seek medical care or could visit a pharmacist.
Some over the counter products currently prescribed are quickly and easily available in community pharmacies where the public can also ask for an NHS consultation with a pharmacist if they are unsure about what treatment they need for minor conditions.
NHS England and NHS Clinical Commissioners are working with GPs, pharmacists and patient groups to develop and refine the proposals which will be consulted on in the New Year, in particular where exemptions may apply.
Further information on these proposals can be found here: NHS England board meeting item 5 – Items which should not be routinely prescribed in primary care: findings of consultation and next steps
For low value medicines, NHS England has consulted on a list of 18 treatments, drawn up with family doctors and pharmacists, deemed to be ineffective, over-priced and of low clinical value.
The Board has today agreed these treatments should no longer be routinely prescribed and in addition recommended that seven products be referred to the Department of Health to be formally considered for the blacklist:
- Homeopathy – no clear or robust evidence to support its use.
- Herbal treatments – no clear or robust evidence to support its use.
- Omega-3 Fatty Acid Compounds (fish oil) – essential fatty acids which can be obtained through diet, low clinical effectiveness.
- Co-proxamol – pain killer which has had its marketing authorisation withdrawn due to safety concerns.
- Rubefacients (excluding topical NSAIDS) – warming muscle rub products, limited evidence.
- Lutein and Antioxidants – used to treat the eye condition age related macular degeneration , low clinical effectiveness.
- Glucosamine and Chondroitin – used for joint pain, low clinical effectiveness.
A joint clinical working group considered the responses to the consultation and agreed that the recommendations for the 18 products consulted on should either remain unchanged (12 products) or be modified or clarified in six cases (Liothyronine, Travel Vaccines, Lidocaine Plasters, Prolonged-release Doxazosin , Trimipramine and Immediate Release Fentanyl).
Further information and the full list of products can be found on the ‘Items which should not be routinely prescribed in primary care’ webpage.